Methods and devices for detecting intensity of light with translucent detector

Abstract
An optical measurement device includes a light source, a first detector, and a second detector. The light source emits light to a measurement site of a patient and one or more detectors detect the light from the light source. At least a portion of a detector is translucent and the light passes through the translucent portion prior to reaching the measurement site. A detector receives the light after attenuation and/or reflection or refraction by the measurement site. A processor determines a light intensity of the light source, a light intensity through a tissue site, or a light intensity of reflected or refracted light based on light detected by the one or more detectors. The processor can estimate a concentration of an analyte at the measurement site or an absorption or reflection at the measurement site.
Description
FIELD OF THE DISCLOSURE

The present disclosure relates to the field of non-invasive optical based sensors that include a translucent detector to detect an intensity of incident light, an intensity of light transmitted through a measurement site, and/or an intensity of light reflected or refracted by a measurement site.


BACKGROUND

Oximetry is the measurement of the oxygen status of blood. Early detection of low blood oxygen is critical in the medical field, for example in critical care and surgical applications, because an insufficient supply of oxygen can result in brain damage and death in a matter of minutes. Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of oxygen supply. A pulse oximetry system consists of a sensor attached to a patient, a monitor, and a cable connecting the sensor and monitor. Conventionally, pulse oximetry sensors include a light source(s) characterized by a plurality of wavelengths of known spectra transmitting optical radiation into or reflecting off a measurement site, such as, body tissue carrying pulsing blood and/or interstitial fluid. After attenuation by tissue and fluids of the measurement site, a photodetection device(s) detects the attenuated light and outputs a detector signal(s) responsive to the detected attenuated light. A signal processing device(s) process the detector(s) signal(s) and outputs a measurement indicative of a blood constituent of interest, such as glucose, oxygen saturation, methemoglobin, carboxyhemoglobin, glycated hemoglobin, respiration rate, pulse rate, total hemoglobin, other physiological parameters, or other data or combinations of data useful in determining a state or trend of wellness of a patient.


The sensor is typically attached to a patient's finger or toe, or a very young patient's foot. For a finger, the sensor is configured so that the light source (for example, an LED) projects light through the fingernail and into the blood vessels and capillaries underneath. The photodiode is positioned at the fingertip opposite the fingernail so as to detect the transmitted light as it emerges from the finger tissues.


SUMMARY

The present disclosure provides an improved sensor design which enables more accurate estimates of incident light, as well as a concentration of one or more analytes of interest present at a measurement site. An optical measurement device according to the present disclosure can include a light source, a first detector, and a second detector. The light source can be configured to emit light to a measurement site, and the first detector can be configured to receive incident light from the light source. At least a portion of the first detector can be translucent and the incident light can pass through the translucent portion prior to reaching the measurement site. The second detector can be configured to receive the light after attenuation by the measurement site.


The device of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. The optical measurement device can be a pulse oximetry device. The measurement site can include a tissue site of a patient. The measurement site can include biological material. The measurement site can include non-biological material.


The device of any of the preceding paragraphs may also include any combination of the following features described in this paragraph, among others described herein. The first detector can be proximal to the light source with respect to the measurement site. The first detector can be proximal to the light source with respect to the second detector. The second detector can be distal to the first detector with respect to the measurement site.


The device of any of the preceding paragraphs may also include any combination of the following features described in this paragraph, among others described herein. The light source can include one or more light emitting diodes (LEDs). The one or more LEDs can be superluminescent light emitting diode (SLED). The light emitted by the light source can be optical radiation of red, infrared, near infrared or other wavelengths. The first detector can be configured to detect the incident light in real-time. The device can include a housing configured to house the light source. The device can further include flex circuitry, flexible connections, or flexible cabling configured to electrically connect the first detector to the housing. The second detector can include one or more multi-detectors, such as a set of multi-detectors.


The device of any of the preceding paragraphs may also include any combination of the following features described in this paragraph, among others described herein. The first detector can include an antireflective (AR) coating layer, a photodiode layer, and a wafer layer. The photodiode layer can include an Indium-Gallium-Arsenide (InGaAs) PIN photodiode and/or a silicon PIN photodiode. The photodiode layer can be as thin as 2 nanometers. The wafer layer can include an N-type Indium Phosphide (N—InP) wafer. The wafer layer can be about 11 micrometers thick. The first detector further can include a metalized surface for anode/cathode bond pads. The first detector can absorb less than 5% of the light emitted by the light source. One or more physiological parameters can be determined based at least in part on a detected light intensity of the light source by the first detector and the detected light intensity after absorption by the tissue site by the second detector.


The present disclosure also provides a method of estimating a concentration of an analyte of interest at a measurement site. A monitoring system can attach to, attached near, or be directed at the measurement site. The method can include receiving incident light from a light source at a first detector. At least one portion of the first detector can be translucent and the incident light can be received by and pass through the at least one translucent portion before reaching a measurement site. The method can further include determining an intensity of incident light based at least in part on the incident light received by the first detector. The method can further include receiving attenuated light at a second detector. The attenuated light can be the light which emerges from the measurement site. The method can further include determining intensity of light through the measurement site based at least in part on the attenuated light received by the second detector. The method can further include estimating a concentration of an analyte of interest at the measurement site based at least in part on the intensity of the incident light and the intensity of the attenuated light.


The method of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. The measurement site can include a tissue site of a patient. The measurement site can include biological material. The measurement site can include non-biological material. The method can further include estimating one or more physiological parameters based at least in part on the estimated concentration of the analyte of interest at the measurement site. The method can further include predicting blood glucose concentration.


The present disclosure also provides an optical measurement device that includes a light source configured to emit light to a measurement site, and a detector that includes a translucent portion. The detector can be configured to detect light as it passes through that translucent portion.


The device of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. The optical measurement device can be a pulse oximetry device. The measurement site can include a tissue site of a patient. The measurement site can include biological material. The measurement site can include non-biological material. The detector can be configured to detect incident light of the light source before light from the light source is attenuated by the measurement site. The detector can be configured to detect light reflected or refracted by the measurement site.


The device of any of the preceding two paragraphs may also include any combination of the following features described in this paragraph, among others described herein. The detector can be a first detector and can be configured to detect light before the light is attenuated by the measurement site. The device can further include a second detector configured to receive the light after attenuation by the measurement site. The first detector can be proximal the tissue site with respect to the second detector.


A system, method, or device having any of the features described herein or illustrated in the drawings.


This disclosure describes embodiments of non-invasive methods, devices, and systems for measuring a blood and/or interstitial fluid constituent (which may also be referred to as an analyte), and/or substance such as oxygen, carboxyhemoglobin, methemoglobin, total hemoglobin, glycated hemoglobin, glucose, proteins, lipids, a percentage thereof (for example, saturation), or for measuring many other physiologically relevant patient characteristics. These characteristics can relate, for example, to pulse rate, hydration, trending information, blood oxygen level and analysis, and the like. For example, these measurements can be taken using a non-invasive optical sensor.


This disclosure describes embodiments of non-invasive methods, devices, and systems for detecting intensity of light emitted from a light source of an optical measurement device. The optical measurement device can include a pulse oximeter and/or a spectrophotometer. An optical measurement device or system can determine the power going into a patient's tissue and estimate a concentration of an analyte of interest at the tissue site. In some cases, the optical measurement device or system can estimate absorption of the tissue.


The optical measurement device can be configured to measure tissue of a patient and includes a light source and one or more detectors. The optical measurement device can be attached to the patient measurement site using adhesives, straps, clips, bandages or other attachment devices. The light source can project light through a tissue site of a patient. A detector can detect the light as it emerges from the light source. At least a portion of the detector can be translucent. Light projected from the light source can pass through the translucent portion of the detector prior to reaching the tissue site of the patient. A detector can also detect light as it emerges from the patient's tissue. In addition or alternatively, a detector can also detect light that is reflected or refracted from the patient's tissue. In some cases, these are the same sensor. In some cases, these are different sensors.


The present disclosure also provides that one or more physiological parameters can be determined based at least in part on a detected light intensity of a light source by a first detector and a detected light intensity after absorption by a tissue site by a second detector. The second detector can include a set of detectors.


The present disclosure also provides embodiments for a method of estimating a concentration of an analyte of interest at a tissue site of a patient by a patient monitoring system is provided. The method includes receiving light from a light source at a first detector wherein at least one portion of the first detector is translucent and the light is received by and passes through the at least one translucent portion before reaching a tissue site of a patient; determining a light intensity of the light source based at least in part on the light received by the first detector; receiving attenuated light at a second detector, wherein the attenuated light is the light which emerges from a tissue site of the patient; determining light intensity through a tissue site based at least in part on the attenuated light received by the second detector; and estimating a concentration of an analyte of interest at the tissue based at least in part on the incident light (for example, an light intensity of the light source) detected by the first detector and the light intensity through the tissue site detected by the second detector. The second detector can include a set of detectors.


For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the inventions have been described herein. It is to be understood that not necessarily all such advantages can be achieved in accordance with any particular embodiment of the inventions disclosed herein. Thus, the inventions disclosed herein can be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other advantages as can be taught or suggested herein.





BRIEF DESCRIPTION OF THE DRAWINGS

Throughout the drawings, reference numbers can be re-used to indicate correspondence between referenced elements. The drawings are provided to illustrate embodiments of the inventions described herein and not to limit the scope thereof.



FIGS. 1A and 1B illustrate block diagram of example optical measurement devices.



FIG. 2 illustrates a flow diagram of example pulse oximetry device and/or patient monitoring device.



FIG. 3A illustrates a side view of an example detector.



FIG. 3B illustrates a top/bottom view of an example detector.



FIG. 4 illustrates examples of light absorption data collected by a detector having varying thickness.





DETAILED DESCRIPTION

Beer's Law (also known as the Beer-Lambert Law) relates the attenuation of light to properties of a material. In particular, Beer's law states that absorbance of a material is proportional to the concentrations of the attenuating species in the material sample. The relationship between these parameters can be expressed as:

A=ϵ*b*c  (1)

where A is the absorbance of the material at a given wavelength of light, ε is the molar absorptivity or extinction coefficient (L mol−1 cm−1), unique to each molecule and varying with wavelength, b is the length of the light path through the material (cm), and c is the concentration of an analyte of interest (mol L−1).


In addition to absorbance, the concentration of an analyte of interest can be determined based on an intensity of the light transmitted through the material (I) and an intensity of incident light (I0). The relationship between these parameters can be expressed as:

I=I0*e−ϵ*b*c  (2)


Accordingly, the concentration c of an analyte of interest can be determined based on a known intensity of light transmitted through the solution I, an intensity of the incident light I0, a pathlength b, and the molar absorptivity ε at a particular wavelength λ.


However, generally, a precise, real-time measurement of intensity of the incident light (I0) is not known. Conventionally, I0 has been measured in a variety of ways which either do not produce accurate measurements or produce measurements with degrading accuracy over time.


For instance, I0 can be measured accurately during manufacturing. However, because the light source will experience real time fluctuations and power degradation over time, using the manufacturing I0 measurement will eventually lead to inaccuracies and miscalculations of physiological parameters such as glucose.


Moreover, I0 can also be determined by sampling a portion of the projected light. However, the sampled portion of light may not accurately represent the entire beam of projected light unless the light is properly mixed. Mixing light properly usually requires an integrating sphere coated with a diffuse reflective material such as a fluoropolymer. Further, accurate light mixing requires a larger diameter sphere which is in opposition to miniaturize a sensor as much as possible.


In other examples, a reference photodiode can be utilized underneath a side of a light source to capture light emitted out the back of a chip. However, this technique does not provide an accurate representation of the light emitted out the front spectrally and it becomes difficult to capture more than one light source on a single reference photodiode if there are multiple light sources in a sensor.


The forgoing difficulties exemplify a need for an improved I0 measuring technique that provides accurate, real-time I0 detection with low quantum efficacy (for example, low light absorption) and takes up limited space. By accurately determining I0, a system can determine various analyte concentrations or changes in concentration in various kinds of biological (for example, living) or non-biological (for example, non-living) material. In some cases, based at least in part on the concentration of an analyte of interest, a system can determine various other predictions or determinations. For example, in pulse oximeter or spectrographic systems, based on the concentration of an analyte of interest, the system can determine or predict physiological parameters, such as glucose or other analyte values. Similar predictions or determinations can be made when the measuring site includes non-biological material.



FIG. 1A illustrates block diagram of an example optical measurement device. The optical measurement device 100 includes a light source 102 configured to emit light towards a measurement site 106, a first detector 104 configured to detect incident light 112 of the light source 102, and a second detector 110 configured to detect light 116 transmitted through the measurement site 106. As illustrated, the first detector 104 is proximal the light source 102 and distal the second detector 110 with respect to the measurement site 106. In addition, the second detector 110 is distal the light source 102 with respect to the first detector 104 and with respect to the measurement site 106. In some cases, the optical measurement device 100 is a pulse oximetry device or a spectrophotometer and the measurement site 106 is a tissue site of a patient. However, the optical measurement device 100 can be any optical measuring device and the measurement site can include any biological or non-biological material.


The light source 102 can include one or more light emitting diodes (LEDs), superluminescent LEDs (SLEDs), lasers, etc. for transmitting optical radiation (for example, light at one or more wavelengths) 112 into or reflecting off the measurement site 106. For ease of reference, the light (for example, the arrows) depicted in FIG. 1A is characterized at multiple stages within the optical measurement device 100. However, in the example illustrated in FIG. 1A, only the light source 102 emits light. The numbered distinctions (112, 114, 116) represent the differing intensities and wavelengths of light from the light source 102 as the light travels from the light source 102 to the second detector 110. For instance, the first set of arrows 112 represents incident light projected from the light source 102 and detected by the first detector 104; the second set of arrows 114 represents light as it emerges from the first detector 104 and reaches the measurement site 106; and the third set of arrows 116 represent light as it emerges from the measurement site 106. Accordingly, each stage of light 112, 114, 116 may have a differing intensity due to, for instance, absorption and/or attenuation.


The first detector 102 is positioned proximal to the light source 102 so as to advantageously detect incident light 112 or an intensity of incident light, I0, as the incident light 112 emerges from the light source 102. This positioning between the light source 102 and first detector 102 allows for a highly accurate real-time I0 detection by the first detector 104 before any significant reduction in intensity of the light projected by the light source 102.


At least a portion of the first detector 104 can be translucent or partially transparent, thereby acting as a window (and a photodiode) from which all light projected from the light source 102 will pass through prior to reaching the measurement site 106. Advantageously, the photodiode (for example, the translucent portion of the first detector 104) receives all (or a substantial portion) of the incident light 112 projected by the light source 102 and can output a signal responsive to the detected light. Thus, unlike the light sampling method mentioned above, the detected light is accurate representation of the light coming from the light source 102. Additionally, the first detector 104 can be positioned such that it detects little or no backscatter light.


Additionally, the first detector 104 can include other advantageous properties (as described in more detail with respect to FIGS. 3-4) that reduce an amount of incident light 112 absorbed by the first detector 104 during detection. Accordingly, the low quantum efficiency (for example, low light absorption) of first detector 104 indicates that the light 114 transmitted to the tissue site 106 is substantially equal to the incident light 112 from the light source 102. For instance, the majority of light (for example, about 90%, 92%, 94%, 96%, or 98% (+/−1%)) of the incident light 112 can reach the measurement site 106 despite first passing through the first detector 104. In other words, the first detector 104 advantageously absorbs a small percentage of the incident light 112. For example, the first detector 104 can absorb less than 10%, less than 5%, or less than 2% (+/− a few %) of the incident light 112.


By permitting the majority of the light 112 to pass through, the first detector 104 is able to generate a signal corresponds to the intensity of incident light 112 without greatly affecting the intensity of light 114 transmitted to the measurement site 106. Accordingly, the incident light 112 and the light 114 emerging from the first detector 104 have substantially similar intensities. Furthermore, in some cases, the small reduction in light intensity caused by the first detector 104 is negligible because the source power is much higher than after the light has traveled through the measurement site 106.


The second detector 110 can include one or more detectors such as a set of multi-detectors. The second detector 110 is distal the light source 102 and proximal the measurement site 106 with respect to the first detector 104. The second detector 110 is positioned to detect the light 116 (or intensity of light 116) transmitted through the material the light 116 as it emerges from the measurement site 106. After attenuation by the measurement site 106, the second detector 110 detects the attenuated light 116 and outputs a signal responsive to the detected attenuated light 116. In some examples, the second detector 110 includes one or more photodiodes that generate one or more currents proportional to the intensity of the detected light 116.


In some cases where the optical measurement device 100 is a pulse oximetry device attached to a patient's finger, the second detector 110 can be positioned at the patient's fingertip opposite the fingernail so as to detect the light 116 as it emerges from the finger tissue site. The pulse oximetry device can include a clothespin-shaped housing (not shown) having a contoured bed conforming generally to the shape of a finger. For instance, the pulse oximetry device can include an enclosure for receiving a patient's finger. The enclosure can be formed by an upper section pivotably connected with a lower section. The upper section can include the light source 102 and the first detector 104, and the lower section can include the second detector 110. The upper section can be biased with the lower section to close together around a pivot point and thereby sandwiching the measurement site 106 (for example, the finger tissue site).



FIG. 1B illustrates block diagram of another example of optical measurement device 100. Similar to FIG. 1A, in this example, the optical measurement device 100 includes a light source 102 and a detector 104. However, in this example, the detector 104 is utilized to detect light transmitted by the light source and/or light reflected or refracted 118 by the measurement site 106. As illustrated, the optical measurement device 100 is configured to be positioned such that the light source 102 is proximal the detector 104 with respect to the tissue site 106.


As described herein, at least a portion of detector 104 can be translucent or partially transparent, thereby acting as a window (and a photodiode) from which all light projected from the light source 102 will pass through prior to reaching the measurement site 106 of the patient. Similarly, the detector 104 can be positioned proximate the measurement site 106 such that it receives light 118 reflected and/or refracted from the measurement site. Thus, the detector 104 can detect a light intensity of the light source 102 and/or light intensity of reflected and/or refracted light 118, and the detector 104 can output one or more signals responsive to the light detections.



FIG. 2 illustrates an example flow diagram for determining a concentration of an analyte of the measurement site using the optical measurement device 100 of FIG. 1A or 1B. At block 220, the light source 102 transmits, projects, or emits light 112 towards the measurement site 106. As described herein, the measurement site 106 can include one or more various biological or non-biological material. For example, the measurement site can be a tissue site of a patient. Further, as described above with respect to FIG. 1A or 1B, the light source 102 can include one or more LEDs or SLEDs for transmitting optical radiation. In some cases, the light source 102 can emit light having multiple wavelengths such as red, infrared (IR), near IR, or the like.


At block 222, the detector 104 detects incident light 112 emitted by the light source 102. As described above with respect to FIG. 1A or 1B, at least one portion of the detector 104 can be translucent. The detector 104 is positioned proximal to the light source 102 with respect to the measurement site 106, and can act as a window from which all, or substantially all, light projected from the light source 102 will pass through prior to reaching the measurement site 106. Additionally, the detector 104 can advantageously have low quantum efficiency, thereby ensuring the light 114 transmitted to the measurement site 106 has substantially the same intensity as the light projected 112 by the light source 102. The detector 104 can include a photodiode that generates a current proportional to the intensity of the incident light 112. Accordingly, using the detector 104, a system advantageously can accurately determine the real time I0 without substantially reducing the intensity of light transmitted to the measurement site 106.


At block 224, a detector can detect light 116 transmitted through the measurement site, after attenuation by the measurement site 106. In addition or alternatively, a detector can detect light 118 transmitted reflected or refracted from the measurement site 106. For example, as illustrated in FIG. 1A, the detector 110 can detect light 116 as it emerges from the measurement site 106. As another example, as illustrated in FIG. 1B, the detector 104 can detect light 118 as it reflects or refracts from the measurement site 106. The detector 104 or 110 detects the light 116 or 118 and outputs a signal responsive to the detected light 116 or 118. For example, the detector 104, 110 can be a photodiode that generates a current proportional to the intensity of the detected light 116, 118.


At block 226, a concentration of an analyte of interest of the measurement site 106 can be determined (for example, by one or more processors). For example, using the relationship of Equation 2, the concentration can be determined based at least in part on the detected incident light, the detected light transmitted through the measurement site, or the detect light reflected or refracted by the measurement site. Furthermore, in some cases, a transmittance of light, an absorbance of light, and/or a reflectance of light can be determined.


At block 228, the system determine one or more parameters based at least in part on the analyte concentration, transmittance of light, absorbance of light, or reflectance of light determined at block 226. For example, when the optical measurement device is a pulse oximeter or a spectrophotometer, the system can utilize a concentration of an analyte of interest, absorbance, transmittance, reflectance, or other data at a tissue site to determine one or more physiological parameters corresponding to a patient. For example, the system can determine or predict a measurement indicative of a blood constituent of interest, such as glucose, oxygen saturation, methemoglobin, carboxyhemoglobin, glycated hemoglobin, respiration rate, pulse rate, total hemoglobin, other physiological parameters, or other data or combinations of data useful in determining a state or trend of wellness of a patient. An inverse model of the collected data at different blood glucose values can be created and used to predict glucose (or other analyte) values based at least in part on the measured tissue absorbance. Some other examples of parameters that can be used in the development of an inverse model include but are not limited to various measured temperatures (LED, tissue, ambient, photodiode, etc.) and absorbance of various reference materials measured real time.


In some examples, a data collection system (not shown) can be provided which includes a signal processor, a user interface connected to the signal processor, a storage device and a network interface device, which are connected to the signal processor. The data collection system can include a user interface, such as a display. The data collection system can also include optional outputs alone or in combination with the display, such as a storage device and a network interface. The signal processor can include processing logic that determines measurements for desired analytes, such as glucose, based on the signals received from the one or more detectors 104, 110. The signal processor can be implemented using one or more microprocessors or subprocessors (for example, cores), digital signal processors, application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs), combinations of the same, and the like.



FIG. 3A illustrates a side view of an example detector 104 of the pulse oximetry device 100 of FIG. 1A. In this example, the detector 104 includes four layers. In other examples, the detector 104 can have fewer or more than four layers. The layers can include the same, additional, or equivalent materials to the layers shown in FIG. 3A.


Here, the top layer 340 and the bottom layer 348 include an anti-reflective and/or anti-glare coating. This coating advantageously improves (for example, lowers) the quantum efficiency of the detector 104 (for example, the percentage of light absorbed by the detector 104) by virtually eliminating reflections of the detector 104. As described above with respect to FIG. 1A, it is desirable for the translucent portion of the detector 104 to pass (and not absorb) the light 112 projected from the light source 102. The less light absorbed by the detector 104, the more accurate the light intensity detected by the detector 104.


The second layer 342 includes a photodiode that converts the light 112 into current. In some examples, at least a portion of the second or photodiode layer 342 can be translucent. The photodiode layer 342 can have varying thicknesses across multiple embodiments. For example, the photodiode layer 342 can be as thick as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nanometers (+/− a few nanometers) or can be as thick as a few micrometers. As mentioned below with respect to FIG. 4, the thickness of the photodiode layer 344 can affect the quantum efficiency or light absorption of the detector 104. Thus, in some examples, the photodiode layer 342 can advantageously be thin to provide improved (for example lowered) quantum efficiency. The photodiode layer 342 can include a combination of one or more of an Indium-Gallium-Arsenide (InGaAs) PIN photodiode or a silicon (Si) PIN photodiode. For example, the photodiode 342 may include a layer of Silicon PIN photodiode and an over-layer of Indium-Gallium-Arsenide (InGaAs) PIN photodiode.


The third layer 344 includes a wafer or thin slice of semiconductor material. In some examples, the third layer 344 includes an N-type Indium Phosphide (N—InP) wafer. The third layer 344 can have one of a plurality of thicknesses. For instance, the third layer 344 can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, 20, 50, 100 micrometers thick (+/− a few micrometers).



FIG. 3B illustrates a top/bottom view of an example detector. Here, the detector 104 has a translucent portion 350 and an opaque portion 349. In some examples, the detector 104 can be fully or mostly translucent. While the translucent portion 350 is depicted as having a circular shape, the translucent portion 350 can take any shape. The detector 104 can include more than one translucent portion.


The opaque portion 349 can include a metalized surface. For example, the opaque portion 349 can include a metalized surface for anode/cathode bond pads. As mentioned above, the with respect to FIG. 3A, the surface of the detector 104 can have an antireflective coating to improve quantum efficiency.


In some examples, the translucent portion can be generally circular and have a diameter of approximately 2, 4, 5, 6, 7, 8 mm (+/− a few millimeters). In some examples the area of the translucent portion can be approximately 5, 6, 7, 10, 20, 40 or 80 square millimeters (+/− a few square millimeters).


The detector 104 can take the shape of a rectangular prism, cube, cylinder, or any other shape. In some examples, the width 354 and/or length 352 of the detector 104 is approximately 3 millimeters. In other examples, the width 354 and/or length 352 can be in the range of 1 to 10 millimeters (+/− a few millimeters).



FIG. 4 illustrates examples of quantum efficiency data of a plurality of detectors 104 having photodiode layers of varying thicknesses. As described above, the projected light 112 from the light source 102 is transmitted through a photodiode layer 342 of the detector 104 prior to reaching the tissue site 106 of the patient. FIG. 4 illustrates how the thickness of the photodiode layer 342 (in this example an InGaAs PIN epilayer) affects the quantum efficiency (and total light absorbed) of the detector 104.


In FIG. 4, the X axis 460 of the line chart 400 indicates the thickness (in nanometers) of the InGaAs PIN epilayer of the detector 104. The Y axis 462 of the line chart 400 indicates the estimated quantum efficiency (also light absorbed) expressed as a percentage. The “quantum efficiency” is the ratio of light absorbed to light received (for example, light projected by the light source). Thus, if all photons of a certain wavelength are absorbed, then the quantum efficiency at that particular wavelength is unity. In other words, low light absorption corresponds to low quantum efficiency.


Line 464 represents data values for projected light with wavelength of 1600 nanometers and line 468 represents data values for projected light with wavelength of 1300 nanometers. As indicated by the positive slopes of the lines 464 and 468, as the thickness of the photodiode layer increases, the total light absorbed by the detector increases. Accordingly, in some examples, the detector 104 can have a thin photodiode layer (for instance, 2 or 3 nm) to advantageously reduce the amount of light absorbed by the detector 104, thereby providing the tissue site 106 with light having intensity similar to that of the light as it emerges from the light source 102.


In addition, lines 464 and 468 of FIG. 4 indicate that as the wavelength of projected light increases, the quantum efficiency decreases. Accordingly, in some examples, the light source emits light with longer wavelength (for instance, approximately 1600 nanometers) to advantageously reduce the amount of light absorbed by the detector 104.


Embodiments have been described in connection with the accompanying drawings. However, it should be understood that the figures may not be drawn to scale. Distances, angles, etc. are merely illustrative and do not necessarily bear an exact relationship to actual dimensions and layout of the devices illustrated. In addition, the foregoing embodiments have been described at a level of detail to allow one of ordinary skill in the art to make and use the devices, systems, methods, etc. described herein. A wide variety of variation is possible. Components, elements, and/or steps can be altered, added, removed, or rearranged. While certain embodiments have been explicitly described, other embodiments will become apparent to those of ordinary skill in the art based on this disclosure.


Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “for example,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or states. Thus, such conditional language is not generally intended to imply that features, elements and/or states are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or states are included or are to be performed in any particular embodiment.


While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As will be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain inventions disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. An optical measurement device comprising: a light source configured to emit light to a measurement site;a first detector positioned within an optical path between the light source and the measurement site, wherein at least a portion of the light emitted by the light source passes through the first detector prior to reaching the measurement site; anda second detector configured to receive the at least a portion of the light after attenuation by the measurement site.
  • 2. The device of claim 1, wherein the light source comprises one or more light emitting diodes, and wherein the measurement site comprises non-biological material.
  • 3. The device of claim 1, wherein the light source comprises one or more superluminescent light emitting diodes, and wherein the measurement site comprises biological material.
  • 4. The device of claim 1, wherein the second detector is configured to be positioned opposite the first detector with respect to the measurement site.
  • 5. The device of claim 1, further comprising: a housing configured to house the light source; andflexible connections or flexible cabling configured to electrically connect the first detector to the housing.
  • 6. The device of claim 1, wherein the first detector comprises an antireflective (AR) coating layer, a photodiode layer, and a wafer layer.
  • 7. The device of claim 1, wherein the first detector comprises an at least partially transparent portion, wherein the at least a portion of light emitted by the light source passes through the at least partially transparent portion.
  • 8. The device of claim 1, wherein the first detector is configured to output a first signal responsive to first light sensed by the first detector, wherein the second detector is configured to output a second signal responsive to second light sensed by the second detector, and wherein a processor receiving the first signal and the second signal or data responsive to the signals is configured to determine one or more physiological parameters of the patient.
  • 9. The device of claim 8, wherein the one or more physiological parameters comprises at least one of oxygen saturation, respiration rate, or pulse rate.
  • 10. The device of claim 8, wherein the one or more physiological parameters corresponds to at least one of glucose, methemoglobin, carboxyhemoglobin, glycated hemoglobin, total hemoglobin.
  • 11. A method of determining one or more physiological parameters, the method comprising: controlling a light source to emit light towards a measurement site, wherein at least a portion of the light passes through a first detector before reaching the measurement site, and wherein the at least a portion of the light is received by a second detector after attenuation by the measurement site;receiving a first signal output by the first detector responsive to first light sensed by the first detector;receiving a second signal output by the second detector responsive to second light sensed by the second detector; anddetermining one or more physiological parameters based at least in part on the first signal and the second signal.
  • 12. The method of claim 11, wherein the one or more physiological parameters comprises blood glucose concentration.
  • 13. The method of claim 11, wherein the measurement site comprises non-biological material.
  • 14. An optical measurement device comprising: a light source configured to emit light toward a measurement site; anda detector positioned within an optical path between the light source and the measurement site, wherein the detector is configured to sense a first portion of the light before the first portion of the light reaches the measurement site, and wherein a second portion of the light passes through the detector before the second portion of the light reaches the measurement site.
  • 15. The device of claim 14, wherein the detector is further configured to detect the second portion of the light after the second portion of the light interacts with the measurement site.
  • 16. The device of claim 15, wherein the detector is configured to output a first signal responsive to the first portion of the light and output a second signal responsive to the second portion of the light, and wherein an oximeter receives the first signal and the second signal and determines one or more physiological parameters of the patient based at least in part on the first signal and the second signal.
  • 17. The device of claim 14, wherein the detector is a first detector, wherein the device further comprises a second detector configured to receive the second portion of the light after the second portion of the light is attenuated by the measurement site.
  • 18. The device of claim 17, wherein the first detector is configured to output a first signal responsive to the first portion of the light, wherein the second detector is configured to output a second signal responsive to the second portion of the light, and wherein an oximeter receives the first signal and the second signal and determines one or more physiological parameters of the patient based at least in part on the first signal and the second signal.
  • 19. The device of claim 14, wherein the light source comprises one or more superluminescent light emitting diodes, and wherein the measurement site comprises non-biological material.
  • 20. The device of claim 14, wherein the light source comprises one or more light emitting diodes, and wherein the measurement site comprises biological material.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority benefit to U.S. Provisional Application No. 62/437,996, entitled “METHODS AND DEVICES FOR DETECTING INTENSITY OF LIGHT WITH TRANSLUCENT DETECTOR,” filed Dec. 22, 2016, which is hereby incorporated herein by reference in its entirety.

US Referenced Citations (762)
Number Name Date Kind
4431429 Booth Feb 1984 A
4443107 Alexander et al. Apr 1984 A
4770536 Golberstein Sep 1988 A
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5163438 Gordon et al. Nov 1992 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5685299 Diab et al. Nov 1997 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5987343 Kinast Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kiani et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6745060 Diab et al. Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6792300 Diab et al. Sep 2004 B1
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6898452 Al-Ali et al. May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7048687 Reuss et al. May 2006 B1
7067893 Mills et al. Jun 2006 B2
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
7132641 Schulz et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7526328 Diab et al. Apr 2009 B2
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7618375 Flaherty Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
RE41317 Parker May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Al-Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175668 Nabutovsky et al. May 2012 B1
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8280473 Al-Ali Oct 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 MacNeish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8690799 Telfort et al. Apr 2014 B2
8700112 Kiani Apr 2014 B2
8702627 Telfort et al. Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8715206 Telfort et al. May 2014 B2
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755535 Telfort et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8790268 Al-Ali Jul 2014 B2
8801613 Al-Ali et al. Aug 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego et al. Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9066680 Al-Ali et al. Jun 2015 B1
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
D755392 Hwang et al. May 2016 S
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
9364181 Kiani et al. Jun 2016 B2
9368671 Wojtczuk et al. Jun 2016 B2
9370325 Al-Ali et al. Jun 2016 B2
9370326 McHale et al. Jun 2016 B2
9370335 Al-ali et al. Jun 2016 B2
9375185 Ali et al. Jun 2016 B2
9386953 Al-Ali Jul 2016 B2
9386961 Al-Ali et al. Jul 2016 B2
9392945 Al-Ali et al. Jul 2016 B2
9397448 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9466919 Kiani et al. Oct 2016 B2
9474474 Lamego et al. Oct 2016 B2
9480422 Al-Ali Nov 2016 B2
9480435 Olsen Nov 2016 B2
9492110 Al-Ali et al. Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9538949 Al-Ali et al. Jan 2017 B2
9538980 Telfort et al. Jan 2017 B2
9549696 Lamego et al. Jan 2017 B2
9554737 Schurman et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9560998 Al-Ali et al. Feb 2017 B2
9566019 Al-Ali et al. Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9591975 Dalvi et al. Mar 2017 B2
9622692 Lamego et al. Apr 2017 B2
9622693 Diab Apr 2017 B2
D788312 Al-Ali et al. May 2017 S
9636055 Al-Ali et al. May 2017 B2
9636056 Al-Ali May 2017 B2
9649054 Lamego et al. May 2017 B2
9662052 Al-Ali et al. May 2017 B2
9668679 Schurman et al. Jun 2017 B2
9668680 Bruinsma et al. Jun 2017 B2
9668703 Al-Ali Jun 2017 B2
9675286 Diab Jun 2017 B2
9687160 Kiani Jun 2017 B2
9693719 Al-Ali et al. Jul 2017 B2
9693737 Al-Ali Jul 2017 B2
9697928 Al-Ali et al. Jul 2017 B2
9717425 Kiani et al. Aug 2017 B2
9717458 Lamego et al. Aug 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
9724024 Al-Ali Aug 2017 B2
9724025 Kiani et al. Aug 2017 B1
9730640 Diab et al. Aug 2017 B2
9743887 Al-Ali et al. Aug 2017 B2
9749232 Sampath et al. Aug 2017 B2
9750442 Olsen Sep 2017 B2
9750443 Smith et al. Sep 2017 B2
9750461 Telfort Sep 2017 B1
9775545 Al-Ali et al. Oct 2017 B2
9775546 Diab et al. Oct 2017 B2
9775570 Al-Ali Oct 2017 B2
9778079 Al-Ali et al. Oct 2017 B1
9782077 Lamego et al. Oct 2017 B2
9782110 Kiani Oct 2017 B2
9787568 Lamego et al. Oct 2017 B2
9788735 Al-Ali Oct 2017 B2
9788768 Al-Ali et al. Oct 2017 B2
9795300 Al-Ali Oct 2017 B2
9795310 Al-Ali Oct 2017 B2
9795358 Telfort et al. Oct 2017 B2
9795739 Al-Ali et al. Oct 2017 B2
9801556 Kiani Oct 2017 B2
9801588 Weber et al. Oct 2017 B2
9808188 Perea et al. Nov 2017 B1
9814418 Weber et al. Nov 2017 B2
9820691 Kiani Nov 2017 B2
9833152 Kiani et al. Dec 2017 B2
9833180 Shakespeare et al. Dec 2017 B2
9839379 Al-Ali et al. Dec 2017 B2
9839381 Weber et al. Dec 2017 B1
20020011568 Diekmann Jan 2002 A1
20060161054 Reuss et al. Jul 2006 A1
20070282478 Al-Ali et al. Dec 2007 A1
20090247984 Lamego et al. Oct 2009 A1
20090275813 Davis Nov 2009 A1
20090275844 Al-Ali Nov 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100317940 Kuhn et al. Dec 2010 A1
20110082711 Poeze et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110230733 Al-Ali Sep 2011 A1
20110237969 Eckerbom et al. Sep 2011 A1
20120165629 Merritt et al. Jun 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130267804 Al-Ali Oct 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130296713 Al-Ali et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331660 Al-Ali et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140081100 Muhsin et al. Mar 2014 A1
20140081175 Telfort Mar 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140180160 Brown et al. Jun 2014 A1
20140187973 Brown et al. Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140276115 Dalvi et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140316217 Purdon et al. Oct 2014 A1
20140316218 Purdon et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140323897 Brown et al. Oct 2014 A1
20140323898 Purdon et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140357966 Al-Ali et al. Dec 2014 A1
20150005600 Blank et al. Jan 2015 A1
20150011907 Purdon et al. Jan 2015 A1
20150012231 Poeze et al. Jan 2015 A1
20150032029 Al-Ali et al. Jan 2015 A1
20150038859 Dalvi et al. Feb 2015 A1
20150045637 Dalvi Feb 2015 A1
20150080754 Purdon et al. Mar 2015 A1
20150087936 Al-Ali et al. Mar 2015 A1
20150094546 Al-Ali Apr 2015 A1
20150097701 Al-Ali et al. Apr 2015 A1
20150099950 Al-Ali et al. Apr 2015 A1
20150099955 Al-Ali et al. Apr 2015 A1
20150101844 Al-Ali et al. Apr 2015 A1
20150106121 Muhsin et al. Apr 2015 A1
20150112151 Muhsin et al. Apr 2015 A1
20150116076 Al-Ali et al. Apr 2015 A1
20150126830 Schurman et al. May 2015 A1
20150165312 Kiani Jun 2015 A1
20150196237 Lamego Jul 2015 A1
20150196249 Brown et al. Jul 2015 A1
20150216459 Al-Ali et al. Aug 2015 A1
20150230755 Al-Ali et al. Aug 2015 A1
20150238722 Al-Ali Aug 2015 A1
20150245773 Lamego et al. Sep 2015 A1
20150245794 Al-Ali Sep 2015 A1
20150257689 Al-Ali et al. Sep 2015 A1
20150272514 Kiani et al. Oct 2015 A1
20150351697 Weber et al. Dec 2015 A1
20150351704 Kiani et al. Dec 2015 A1
20150359429 Al-Ali et al. Dec 2015 A1
20150366507 Blank Dec 2015 A1
20150380875 Coverston et al. Dec 2015 A1
20160029932 Al-Ali Feb 2016 A1
20160051205 Al-Ali et al. Feb 2016 A1
20160058347 Reichgott et al. Mar 2016 A1
20160066823 Al-Ali et al. Mar 2016 A1
20160066824 Al-Ali et al. Mar 2016 A1
20160072429 Kiani et al. Mar 2016 A1
20160081552 Wojtczuk Mar 2016 A1
20160095543 Telfort et al. Apr 2016 A1
20160095548 Al-Ali et al. Apr 2016 A1
20160103598 Al-Ali et al. Apr 2016 A1
20160143548 Al-Ali May 2016 A1
20160166182 Al-Ali et al. Jun 2016 A1
20160166183 Poeze et al. Jun 2016 A1
20160192869 Kiani et al. Jul 2016 A1
20160196388 Lamego Jul 2016 A1
20160197436 Barker et al. Jul 2016 A1
20160213281 Eckerbom et al. Jul 2016 A1
20160228043 O'Neil et al. Aug 2016 A1
20160233632 Scruggs et al. Aug 2016 A1
20160234944 Schmidt et al. Aug 2016 A1
20160270735 Diab et al. Sep 2016 A1
20160283665 Sampath et al. Sep 2016 A1
20160287090 Al-Ali et al. Oct 2016 A1
20160287786 Kiani Oct 2016 A1
20160296169 McHale et al. Oct 2016 A1
20160310052 Al-Ali et al. Oct 2016 A1
20160314260 Kiani Oct 2016 A1
20160324486 Al-Ali et al. Nov 2016 A1
20160324488 Olsen Nov 2016 A1
20160327984 Al-Ali et al. Nov 2016 A1
20160328528 Al-Ali et al. Nov 2016 A1
20160331332 Al-Ali Nov 2016 A1
20160367173 Dalvi et al. Dec 2016 A1
20170000394 Al-Ali et al. Jan 2017 A1
20170007134 Al-Ali et al. Jan 2017 A1
20170007190 Al-Ali et al. Jan 2017 A1
20170007198 Al-Ali et al. Jan 2017 A1
20170014083 Diab et al. Jan 2017 A1
20170014084 Al-Ali et al. Jan 2017 A1
20170027456 Kinast et al. Feb 2017 A1
20170042488 Muhsin Feb 2017 A1
20170055851 Al-Ali Mar 2017 A1
20170055882 Al-Ali et al. Mar 2017 A1
20170055887 Al-Ali Mar 2017 A1
20170055896 Al-Ali et al. Mar 2017 A1
20170079594 Telfort et al. Mar 2017 A1
20170086723 Al-Ali et al. Mar 2017 A1
20170143281 Olsen May 2017 A1
20170147774 Kiani May 2017 A1
20170156620 Al-Ali et al. Jun 2017 A1
20170173632 Al-Ali Jun 2017 A1
20170187146 Kiani et al. Jun 2017 A1
20170188919 Al-Ali et al. Jul 2017 A1
20170196464 Jansen et al. Jul 2017 A1
20170196470 Lamego et al. Jul 2017 A1
20170202490 Al-Ali et al. Jul 2017 A1
20170224231 Al-Ali Aug 2017 A1
20170224262 Al-Ali Aug 2017 A1
20170228516 Sampath et al. Aug 2017 A1
20170245790 Al-Ali et al. Aug 2017 A1
20170251974 Shreim et al. Sep 2017 A1
20170251975 Shreim et al. Sep 2017 A1
20170258403 Abdul-Hafiz et al. Sep 2017 A1
Non-Patent Literature Citations (1)
Entry
International Search Report and Written Opinion, re PCT Application No. PCT/US2017/067909, dated Mar. 15, 2018.
Related Publications (1)
Number Date Country
20180199871 A1 Jul 2018 US
Provisional Applications (1)
Number Date Country
62437996 Dec 2016 US